Douglasg Johns News Today : Breaking News, Live Updates & Top Stories | Vimarsana

What if the cholesterol-crushing efficacy of current PCSK9 inhibitors came in a pill instead of a syringe? That s one possibility for a Merck agent in the earliest stages of human trials.

New jerseyUnited statesWashington universityAnnec goldbergDouglasg johnsSanofi regeneronAmerican heart associationEuropean unionWashington university school of medicineScientific sessionsWashington university schoolIpid managementRoprotein convertase subtilisin kexin type 9Nucleoside reverse transcriptase inhibitorsUcleoside analogNhibitor nucleoside reverse transcriptase